Blue Earth Diagnostics, Inc. (U.S.)的动态

Small molecule #therapeutics have had a powerful impact on patients for generations. As #synbio-derived therapeutics offer a new generation of #medicine, what does this mean for small molecule modalities? Join the discussion at #SynBioBeta2024: https://lnkd.in/eShayXpi

Postoperative Pain Pipeline Insights and Analysis 2024: FDA Approvals and Market Developments MOA, ROA by DelveInsight | Allay Therapeutics, SiteOne Therapeutics, LipoCure, Flexion Therapeutics: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Postoperative Pain pipeline constitutes 45+ key companies continuously working towards developing 50+ Postoperative Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced plans to expand its MAVERIC clinical development program with the launch of MAVERIC-2, a late-stage trial aimed at evaluating its lead drug candidate, CardiolRx, in patients with recurrent pericarditis. The trial is expected to begin in Q4 2024 at major pericardial disease centers in the USand Europe. The MAVERIC-2 trial will investigate the potential of CardiolRx in patients who have discontinued interleukin-1 (IL-1) blocker therapy, a common third-line treatment for recurrent pericarditis. The study is intended to pave the way for an accelerated regulatory approval process ahead of the company's planned... https://ow.ly/2NBB105ME4M

Great to see some positive news in the allogeneic CAR T space. Especially for a disease like Multiple Myeloma where commercial companies have struggled to meet demand. Also interest to see prominent use of a non-viral gene delivery platform, which I think we'll see more of very soon. #CART #celltherapy #genetherapy.

Part 2 of CEO Howard Berman's recent interview with?Pharmaceutical Executive's Don Tracy is live now on their website where they talk about next steps for Coya 302. Watch the video at this link: $Coya #Coyatherapeutics #ALS #neurodegenerative

LaNova Medicines Begins the P-I Trial of LM-299 for Solid Tumors and Concludes Series C1 Financing #lanovamedicines #lm299 #solidtumors #pharma #seriesC1financing #seriesC2financing

Thoughts on this? >> J&J’s multiple myeloma therapies drive oncology business despite slow Carvykti sales >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #productmarketing #biotech #pharma

Five Quick Facts to Know About Biosimilars: The biosimilar space continues to grow, with key focuses around retina and oncology, but adoption remains slow in the United States. #finance #pharmacy #lifesciences

Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy: Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 20+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Thoughts on this? >> J&J’s multiple myeloma therapies drive oncology business despite slow Carvykti sales >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #healthcare #pharmaceutical #pharma